Dongwen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dongwen Wang has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
Gaohaer Kadeerhan
Chinese Academy of Medical Sciences and Peking Central Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital Union Medical College Guangdong Province 518116 Shenzhen China
11 shared publicationsBo Wu
Department of Urology First Hospital of Shanxi Medical University 030001 Taiyuan Province Shanxi China
10 shared publicationsJin Zhang
Department of Urology First Hospital of Shanxi Medical University 030001 Taiyuan Province Shanxi China
7 shared publicationsWenmin Guo
Department of Urology Chinese Academy of Medical Sciences and Peking National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Union Medical College Guangdong Province 518116 Shenzhen China
7 shared publicationsXuhui Zhang
Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China
6 shared publicationsYuan Shao
Tianjin Medical University, Tianjin, China
6 shared publications
Latest Publications
- Open Access
- 11 February 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (9) , 4551-4565
PSMA-targeted fluorescent probe for NIR-II imaging in prostate cancer intraoperative navigation and tumor margin mapping
Accurate delineation of tumor margins during prostate cancer surgery remains challenging due to limited intraoperative visualization and insufficient molecular specificity. Here, we developed a PSMA-targeted near-infrared fluorescent probe, PSMA-12-IRDye800CW, that leverages the clinically used IRDye800CW scaffold and its extended emission tail beyond 1000 nm to support NIR-II fluorescence imaging for intraoperative navigation and histopathological margin mapping. Methods: PSMA-12-IRDye800CW integrates a PSMA-targeting ligand with an albumin-binding linker to enable active targeting and circulation-assisted tumor accumulation. Optical properties, targeting specificity, imaging performance, and biosafety were evaluated in vitro, in prostate cancer xenograft models with direct comparison to indocyanine green (ICG) across defined time points, and in clinical formalin-fixed paraffin-embedded (FFPE) prostate specimens with matched histopathology and PSMA immunohistochemistry. Results: In 22Rv1 (PSMA⁺) xenografts, PSMA-12-IRDye800CW achieved significantly higher tumor-to-background ratios than ICG at key surgical-relevant time points, including 24 h (4.31 ± 0.17 vs. 2.65 ± 0.15), providing a practical imaging window for fluorescence-guided resection. Ex vivo tissue analyses further confirmed significantly higher fluorescence in tumors than in muscle and skin. In human FFPE specimens, fluorescence showed pathology-aligned spatial correspondence with PSMA immunohistochemistry, and fluorescence intensity correlated strongly with PSMA H-scores (R² = 0.8616, P < 0.0001), enabling micron-scale histopathological margin mapping. Multimodal biosafety assessments indicated favorable biocompatibility with no evident acute toxicity and low immunogenic potential. Conclusions: PSMA-12-IRDye800CW enables NIR-II fluorescence imaging-assisted intraoperative navigation and provides a quantitative, pathology-anchored readout for histopathological margin mapping in prostate cancer, supporting further clinical validation of this PSMA-targeted strategy for fluorescence-guided surgery and margin assessment.
- 11 February 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (9) , 4551-4565
Open AccessPSMA-targeted fluorescent probe for NIR-II imaging in prostate cancer intraoperative navigation and tumor margin mapping
Accurate delineation of tumor margins during prostate cancer surgery remains challenging due to limited intraoperative visualization and insufficient molecular specificity. Here, we developed a PSMA-targeted near-infrared fluorescent probe, PSMA-12-IRDye800CW, that leverages the clinically used IRDye800CW scaffold and its extended emission tail beyond 1000 nm to support NIR-II fluorescence imaging for intraoperative navigation and histopathological margin mapping. Methods: PSMA-12-IRDye800CW integrates a PSMA-targeting ligand with an albumin-binding linker to enable active targeting and circulation-assisted tumor accumulation. Optical properties, targeting specificity, imaging performance, and biosafety were evaluated in vitro, in prostate cancer xenograft models with direct comparison to indocyanine green (ICG) across defined time points, and in clinical formalin-fixed paraffin-embedded (FFPE) prostate specimens with matched histopathology and PSMA immunohistochemistry. Results: In 22Rv1 (PSMA⁺) xenografts, PSMA-12-IRDye800CW achieved significantly higher tumor-to-background ratios than ICG at key surgical-relevant time points, including 24 h (4.31 ± 0.17 vs. 2.65 ± 0.15), providing a practical imaging window for fluorescence-guided resection. Ex vivo tissue analyses further confirmed significantly higher fluorescence in tumors than in muscle and skin. In human FFPE specimens, fluorescence showed pathology-aligned spatial correspondence with PSMA immunohistochemistry, and fluorescence intensity correlated strongly with PSMA H-scores (R² = 0.8616, P < 0.0001), enabling micron-scale histopathological margin mapping. Multimodal biosafety assessments indicated favorable biocompatibility with no evident acute toxicity and low immunogenic potential. Conclusions: PSMA-12-IRDye800CW enables NIR-II fluorescence imaging-assisted intraoperative navigation and provides a quantitative, pathology-anchored readout for histopathological margin mapping in prostate cancer, supporting further clinical validation of this PSMA-targeted strategy for fluorescence-guided surgery and margin assessment.
- Open Access
Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth
- Open Access
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1688048
Prostate-specific membrane antigen targeted organic semiconducting polymer nanoparticles for enhanced photothermal therapy of prostate cancer
Photothermal therapy (PTT) in the second near-infrared window (NIR-II, 1000–1700 nm) enables deep-tissue penetration and reduced off-target damage, offering a promising approach for localized cancer ablation. A major challenge, however, lies in achieving efficient and tumor-specific accumulation of photothermal agents. In this study, we developed a prostate-specific membrane antigen (PSMA)-targeted NIR-II photothermal nanoplatform based on an organic semiconducting polymer (OSP 12 ). The OSP 12 core was encapsulated with DSPE-PEG-Mal and covalently conjugated with ACUPA, a high-affinity PSMA ligand, to generate PSMA-OSP 12 nanoparticles (NPs). These nanoparticles exhibited strong NIR-II fluorescence emission and high photothermal conversion efficiency under 808 nm excitation; notably, at 1.0 W/cm 2 for 5 min the maximum solution temperature reached 77.3°C, and the particles showed excellent photothermal stability, retaining >90.0% of their peak heating performance after five on/off irradiation cycles. Owing to their enhanced targeting capability and robust photothermal stability, PSMA-OSP 12 NPs enabled effective photothermal ablation of PSMA-positive prostate tumors with minimal systemic toxicity in vivo . Collectively, our findings demonstrate that PSMA-OSP 12 NPs constitute a potent and precise NIR-II photothermal nanoplatform for prostate cancer treatment.
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1688048
Open AccessProstate-specific membrane antigen targeted organic semiconducting polymer nanoparticles for enhanced photothermal therapy of prostate cancer
Photothermal therapy (PTT) in the second near-infrared window (NIR-II, 1000–1700 nm) enables deep-tissue penetration and reduced off-target damage, offering a promising approach for localized cancer ablation. A major challenge, however, lies in achieving efficient and tumor-specific accumulation of photothermal agents. In this study, we developed a prostate-specific membrane antigen (PSMA)-targeted NIR-II photothermal nanoplatform based on an organic semiconducting polymer (OSP 12 ). The OSP 12 core was encapsulated with DSPE-PEG-Mal and covalently conjugated with ACUPA, a high-affinity PSMA ligand, to generate PSMA-OSP 12 nanoparticles (NPs). These nanoparticles exhibited strong NIR-II fluorescence emission and high photothermal conversion efficiency under 808 nm excitation; notably, at 1.0 W/cm 2 for 5 min the maximum solution temperature reached 77.3°C, and the particles showed excellent photothermal stability, retaining >90.0% of their peak heating performance after five on/off irradiation cycles. Owing to their enhanced targeting capability and robust photothermal stability, PSMA-OSP 12 NPs enabled effective photothermal ablation of PSMA-positive prostate tumors with minimal systemic toxicity in vivo . Collectively, our findings demonstrate that PSMA-OSP 12 NPs constitute a potent and precise NIR-II photothermal nanoplatform for prostate cancer treatment.
- 4 December 2025
- Published by Elsevier in Life Sciences
- Vol. 386, 124137
Loss of PINCH2 leads to myogenic urinary retention in mice
- 4 December 2025
- Published by Elsevier in Life Sciences
- Vol. 386, 124137
Loss of PINCH2 leads to myogenic urinary retention in mice
- Open Access
- 13 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29651
Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma
Interleukin-2 Receptor Subunit Gamma (IL2RG) has been implicated in various cancers, but its role in clear cell renal cell carcinoma (ccRCC) remains unclear. This study aimed to explore IL2RG expression, its relationship with IL2RG -related lncRNAs (IRLs). Gene expression and clinical data for ccRCC were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus(GEO) database. The IRL signature was constructed using Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis. Clinical data validated the diagnostic value of the signature. The prognostic value of the signal was assessed using Kaplan-Meier analysis and Receiver Operating Characteristic (ROC) curves. The prognostic value of the nomogram was further evaluated through calibration curves, ROC curves, and Decision Curve Analysis (DCA). Gene set enrichment analysis (GSEA), single-sample GSEA (ssGSEA), CIBERSORT algorithms, and TISCH2 database were applied to analyze immune function and immune cell infiltration in different risk groups. Clinical treatment differences among populations with varying risks and susceptibilities were predicted using R packages. The expression of IL2RG and key lncRNAs was validated by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). IL2RG was significantly upregulated in ccRCC tissues and correlated with advanced clinical stages (p < 0.001). High IL2RG expression was linked to worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) (p < 0.05). A 6-IRLs signature was identified, and the resulting model accurately predicted survival outcomes. Immune-related pathways were enriched in high-risk patients, and drug sensitivity analysis indicated that high-risk patients were more responsive to sunitinib and temsirolimus. IL2RG and its related 6-IRLs are potential biomarkers for ccRCC progression. The 6-IRLs model provides a robust tool for predicting prognosis and guiding therapeutic decisions.
- 13 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29651
Open AccessPrognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma
Interleukin-2 Receptor Subunit Gamma (IL2RG) has been implicated in various cancers, but its role in clear cell renal cell carcinoma (ccRCC) remains unclear. This study aimed to explore IL2RG expression, its relationship with IL2RG -related lncRNAs (IRLs). Gene expression and clinical data for ccRCC were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus(GEO) database. The IRL signature was constructed using Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis. Clinical data validated the diagnostic value of the signature. The prognostic value of the signal was assessed using Kaplan-Meier analysis and Receiver Operating Characteristic (ROC) curves. The prognostic value of the nomogram was further evaluated through calibration curves, ROC curves, and Decision Curve Analysis (DCA). Gene set enrichment analysis (GSEA), single-sample GSEA (ssGSEA), CIBERSORT algorithms, and TISCH2 database were applied to analyze immune function and immune cell infiltration in different risk groups. Clinical treatment differences among populations with varying risks and susceptibilities were predicted using R packages. The expression of IL2RG and key lncRNAs was validated by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). IL2RG was significantly upregulated in ccRCC tissues and correlated with advanced clinical stages (p < 0.001). High IL2RG expression was linked to worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) (p < 0.05). A 6-IRLs signature was identified, and the resulting model accurately predicted survival outcomes. Immune-related pathways were enriched in high-risk patients, and drug sensitivity analysis indicated that high-risk patients were more responsive to sunitinib and temsirolimus. IL2RG and its related 6-IRLs are potential biomarkers for ccRCC progression. The 6-IRLs model provides a robust tool for predicting prognosis and guiding therapeutic decisions.
- Open Access
- 6 August 2025
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 14 (1) , 1-22
Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-to-date overview based on the Global Burden of Disease 2021
Background: The burden of genitourinary cancers has significantly changed in China over the recent decades. This study aims to identify the epidemiological trends and disparities in four common genitourinary cancers, including bladder, kidney, prostate, and testicular cancers, to inform public health strategies and interventions. Methods: Based on the Global Burden of Disease Study 2021, we examined incident cases, mortality, age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), mortality-to-incidence ratios (MIRs), and risk factors for four genitourinary cancers globally and in the East Asia and Pacific, China, Japan, the Republic of Korea, the United States, and the United Kingdom from 1990 to 2021 across four specified age groups: 0–14, 15–49, 50–74, and ≥ 75 years. Trend analysis was conducted using Joinpoint analysis to calculate the average annual percentage changes (AAPCs). Decomposition analysis was performed to identify the population-level factors contributing to these trends. Results: In 2021, China reported approximately 266,887 incident cases and 108,589 deaths from genitourinary cancers, exhibiting distinct age-related patterns. ASIRs for male kidney cancer among those aged 0–14 years and testicular cancer among those aged ≥ 75 years, as well as ASMRs for male bladder cancer aged 15–49 years and testicular cancer aged ≥ 75 years, were higher in China than in the studied regions and countries. The MIRs for genitourinary cancers were generally higher in China. From 1990 to 2021, a notable increase in ASIRs for genitourinary cancers in both sexes, as well as ASMRs for male kidney and prostate cancers, across age groups ranging from 15 to 49 years to ≥ 75 years was observed in China, accompanied by higher AAPCs. The decomposition analysis identified the key population-level contributors to the incidence and mortality trends of genitourinary cancers, highlighting the varying influences of aging, population growth, and epidemiological changes. Smoking-related genitourinary cancer deaths remained high in Chinese males, and mortality related to high body mass index for kidney cancer and elevated fasting plasma glucose levels for bladder cancer also increased. Conclusions: The distinct age-specific patterns, elevated rates within specific age groups, and marked upward temporal trends of genitourinary cancers in China underscore the critical need for targeted, age-stratified public health interventions.
- 6 August 2025
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 14 (1) , 1-22
Open AccessIncidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-to-date overview based on the Global Burden of Disease 2021
Background: The burden of genitourinary cancers has significantly changed in China over the recent decades. This study aims to identify the epidemiological trends and disparities in four common genitourinary cancers, including bladder, kidney, prostate, and testicular cancers, to inform public health strategies and interventions. Methods: Based on the Global Burden of Disease Study 2021, we examined incident cases, mortality, age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), mortality-to-incidence ratios (MIRs), and risk factors for four genitourinary cancers globally and in the East Asia and Pacific, China, Japan, the Republic of Korea, the United States, and the United Kingdom from 1990 to 2021 across four specified age groups: 0–14, 15–49, 50–74, and ≥ 75 years. Trend analysis was conducted using Joinpoint analysis to calculate the average annual percentage changes (AAPCs). Decomposition analysis was performed to identify the population-level factors contributing to these trends. Results: In 2021, China reported approximately 266,887 incident cases and 108,589 deaths from genitourinary cancers, exhibiting distinct age-related patterns. ASIRs for male kidney cancer among those aged 0–14 years and testicular cancer among those aged ≥ 75 years, as well as ASMRs for male bladder cancer aged 15–49 years and testicular cancer aged ≥ 75 years, were higher in China than in the studied regions and countries. The MIRs for genitourinary cancers were generally higher in China. From 1990 to 2021, a notable increase in ASIRs for genitourinary cancers in both sexes, as well as ASMRs for male kidney and prostate cancers, across age groups ranging from 15 to 49 years to ≥ 75 years was observed in China, accompanied by higher AAPCs. The decomposition analysis identified the key population-level contributors to the incidence and mortality trends of genitourinary cancers, highlighting the varying influences of aging, population growth, and epidemiological changes. Smoking-related genitourinary cancer deaths remained high in Chinese males, and mortality related to high body mass index for kidney cancer and elevated fasting plasma glucose levels for bladder cancer also increased. Conclusions: The distinct age-specific patterns, elevated rates within specific age groups, and marked upward temporal trends of genitourinary cancers in China underscore the critical need for targeted, age-stratified public health interventions.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 9807-9823
Enhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis
Prostate-specific membrane antigen (PSMA) is a well-established biomarker overexpressed in prostate cancer (PCa). However, existing PSMA-targeted imaging probes suffer from radiation exposure, limited tissue penetration, and inadequate intraoperative performance. To overcome these challenges, we developed a novel near-infrared-II (NIR-II) fluorescent nanoprobe for both in vivo and ex vivo imaging of PCa. An organic semiconducting polymer (OSP12) with strong NIR-II fluorescence and excellent photostability was self-assembled into nanoparticles (NPs) using DSPE-PEG-Mal. These OSP12 NPs were then conjugated with ACUPA-SH, (S)-2-[3-((S)-5-amino-1-carboxypentyl)ureido]pentanedioic acid, a thiol-modified glutamate-urea-lysine derivative that specifically targets PSMA, via a maleimide-thiol click reaction to form PSMA-OSP12 NPs. The probe's targeting specificity was assessed using PSMA positive and negative cell lines under NIR-II imaging. For in vivo evaluation, subcutaneous xenograft tumors were established in BALB/c nude mice. Animals were randomly assigned to PSMA-OSP12 NP, blocking (ACUPA pre-injection), and control (OSP12 NPs) groups (n = 3 per group). Ex vivo tumor slice imaging was performed on fresh tissue sections. Biosafety was evaluated in healthy mice (n=5) through hematological, biochemical, and histopathological analyses. PSMA-OSP12 NPs exhibited excellent optical properties in the NIR-II window, including high photostability, negligible autofluorescence, and deep tissue penetration. In vitro assays confirmed selective binding to PSMA-positive cells, while in vivo imaging demonstrated sustained tumor accumulation with a peak TBR of 7.40 ± 1.28 at 48 h post-injection. This performance significantly surpassed OTL78 and Cy-KUE-OA, enabling flexible surgical planning and real-time intraoperative guidance. In ex vivo tissue imaging, PSMA-OSP12 NPs provided high-contrast tumor delineation without systemic administration. Biosafety evaluations revealed no significant systemic toxicity, and biodistribution analysis indicated hepatic metabolism and biliary clearance. PSMA-OSP12 NPs are a promising NIR-II fluorescent probe with excellent tumor specificity, deep tissue imaging capability, and good biocompatibility, supporting their application in fluorescence-guided surgery and ex vivo tumor evaluation.
- 1 August 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 9807-9823
Open AccessEnhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis
Prostate-specific membrane antigen (PSMA) is a well-established biomarker overexpressed in prostate cancer (PCa). However, existing PSMA-targeted imaging probes suffer from radiation exposure, limited tissue penetration, and inadequate intraoperative performance. To overcome these challenges, we developed a novel near-infrared-II (NIR-II) fluorescent nanoprobe for both in vivo and ex vivo imaging of PCa. An organic semiconducting polymer (OSP12) with strong NIR-II fluorescence and excellent photostability was self-assembled into nanoparticles (NPs) using DSPE-PEG-Mal. These OSP12 NPs were then conjugated with ACUPA-SH, (S)-2-[3-((S)-5-amino-1-carboxypentyl)ureido]pentanedioic acid, a thiol-modified glutamate-urea-lysine derivative that specifically targets PSMA, via a maleimide-thiol click reaction to form PSMA-OSP12 NPs. The probe's targeting specificity was assessed using PSMA positive and negative cell lines under NIR-II imaging. For in vivo evaluation, subcutaneous xenograft tumors were established in BALB/c nude mice. Animals were randomly assigned to PSMA-OSP12 NP, blocking (ACUPA pre-injection), and control (OSP12 NPs) groups (n = 3 per group). Ex vivo tumor slice imaging was performed on fresh tissue sections. Biosafety was evaluated in healthy mice (n=5) through hematological, biochemical, and histopathological analyses. PSMA-OSP12 NPs exhibited excellent optical properties in the NIR-II window, including high photostability, negligible autofluorescence, and deep tissue penetration. In vitro assays confirmed selective binding to PSMA-positive cells, while in vivo imaging demonstrated sustained tumor accumulation with a peak TBR of 7.40 ± 1.28 at 48 h post-injection. This performance significantly surpassed OTL78 and Cy-KUE-OA, enabling flexible surgical planning and real-time intraoperative guidance. In ex vivo tissue imaging, PSMA-OSP12 NPs provided high-contrast tumor delineation without systemic administration. Biosafety evaluations revealed no significant systemic toxicity, and biodistribution analysis indicated hepatic metabolism and biliary clearance. PSMA-OSP12 NPs are a promising NIR-II fluorescent probe with excellent tumor specificity, deep tissue imaging capability, and good biocompatibility, supporting their application in fluorescence-guided surgery and ex vivo tumor evaluation.
- Open Access
- 2 July 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-17
The impact of surgery and survival prediction in patients with bladder neuroendocrine carcinoma: a novel propensity score-matched population-based cohort study
To evaluate the effects of surgical interventions on individuals diagnosed with bladder neuroendocrine carcinoma (BNEC). Data were gathered from the Surveillance, Epidemiology, and End Results (SEER) database for this retrospective analysis. No-surgery procedures included TURBT, cryotherapy, excisional biopsy, or partial cystectomy. Surgery was categorized as cystectomy, radical cystectomy, or a more complex surgical intervention, such as exenteration. A propensity score overlap weight (PSOW) analysis was performed to adjust statistical influences between the two groups. Prognostic factors related to cancer-specific survival (CSS) and overall survival (OS) were assessed using Cox proportional hazard regression. A total of 2,442 participants were divided into two groups: no-surgery group (n = 1860) and surgery group (n = 582). Individuals in the no-surgery cohort showed a preference for radiation therapy (29.5% compared to 6.7%), whereas individuals in the surgery cohort were more prone to receiving chemotherapy (71.5% compared to 56.6%) as part of their treatment regimen. Surgery was determined to have a strong correlation with increased rates of OS (hazard ratio (HR) = 0.564, 95% confidence interval (CI) = 0.497–0.639, P < 0.001) and CSS (HR = 0.628, 95% CI 0.539–0.732, P < 0.001) results in BNEC patients. After PSOW, 307 patients were selected for each group. Surgical intervention demonstrated a notable enhancement in OS (P < 0.001) and CSS (P < 0.001) than those patients in the no-surgery group. Among the chemotherapy population, the median survival of patients in the surgery group was significantly higher when compared to those in the no-surgery group. Furthermore, individuals diagnosed with stage I (OS, HR = 0.202, 95% CI 0.112–0.366, P < 0.001; CSS HR = 0.198, 95% CI 0.083–0.472, P < 0.001) and II (OS HR = 0.417, 95% CI 0.331–0.525, P < 0.001; CSS HR = 0.415, 95% CI 0.307–0.561, P < 0.001) tumors who underwent surgical procedures exhibited improved long-term survival rates, whereas no surgical advantage was evident in later stages. In the early stages of BNEC, individuals who undergo surgery experience improved survival rates. Therefore, it is important to carefully consider surgical treatment for patients with advanced BNEC.
- 2 July 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-17
Open AccessThe impact of surgery and survival prediction in patients with bladder neuroendocrine carcinoma: a novel propensity score-matched population-based cohort study
To evaluate the effects of surgical interventions on individuals diagnosed with bladder neuroendocrine carcinoma (BNEC). Data were gathered from the Surveillance, Epidemiology, and End Results (SEER) database for this retrospective analysis. No-surgery procedures included TURBT, cryotherapy, excisional biopsy, or partial cystectomy. Surgery was categorized as cystectomy, radical cystectomy, or a more complex surgical intervention, such as exenteration. A propensity score overlap weight (PSOW) analysis was performed to adjust statistical influences between the two groups. Prognostic factors related to cancer-specific survival (CSS) and overall survival (OS) were assessed using Cox proportional hazard regression. A total of 2,442 participants were divided into two groups: no-surgery group (n = 1860) and surgery group (n = 582). Individuals in the no-surgery cohort showed a preference for radiation therapy (29.5% compared to 6.7%), whereas individuals in the surgery cohort were more prone to receiving chemotherapy (71.5% compared to 56.6%) as part of their treatment regimen. Surgery was determined to have a strong correlation with increased rates of OS (hazard ratio (HR) = 0.564, 95% confidence interval (CI) = 0.497–0.639, P < 0.001) and CSS (HR = 0.628, 95% CI 0.539–0.732, P < 0.001) results in BNEC patients. After PSOW, 307 patients were selected for each group. Surgical intervention demonstrated a notable enhancement in OS (P < 0.001) and CSS (P < 0.001) than those patients in the no-surgery group. Among the chemotherapy population, the median survival of patients in the surgery group was significantly higher when compared to those in the no-surgery group. Furthermore, individuals diagnosed with stage I (OS, HR = 0.202, 95% CI 0.112–0.366, P < 0.001; CSS HR = 0.198, 95% CI 0.083–0.472, P < 0.001) and II (OS HR = 0.417, 95% CI 0.331–0.525, P < 0.001; CSS HR = 0.415, 95% CI 0.307–0.561, P < 0.001) tumors who underwent surgical procedures exhibited improved long-term survival rates, whereas no surgical advantage was evident in later stages. In the early stages of BNEC, individuals who undergo surgery experience improved survival rates. Therefore, it is important to carefully consider surgical treatment for patients with advanced BNEC.
- Open Access
- 15 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1203
Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach
Background: Bladder cancer (BC) is a common malignancy in the urinary system, with an increasing incidence rate. Immune cell infiltration within the tumor microenvironment (TME) plays a crucial role in BC progression and treatment response. However, the immune cell composition of the TME presents a significant challenge to the effectiveness of current therapeutic strategies. Methods: We performed bidirectional Mendelian randomization (MR) analysis to investigate the impact of immune cells on BC risk. Single nucleotide polymorphisms (SNPs) related to immune cells were annotated, and candidate genes associated with BC risk were identified. Differential expression analysis identified immune-related differentially expressed genes (iDEGs), and a protein–protein interaction (PPI) network along with functional enrichment analysis were conducted to explore their roles in tumor development. Machine learning-based feature selection was applied to identify potential biomarkers and therapeutic targets. Results: MR analysis revealed eight immune cell subtypes significantly associated with BC. Using SNPs linked to these immune cells, 129 candidate genes were identified through the SNPense tool and cross-referenced with differentially expressed genes in BC, resulting in identification of 28 iDEGs. Machine learning identified five potential diagnostic biomarkers (COLEC12, TMCC1, CEP55, KLK3, COL4A1) with an AUC of 0.903, which are implicated in immune modulation and cancer progression. Conclusions: This study provides new insights into immune mechanisms in BC and identifies promising biomarkers for early diagnosis and therapeutic intervention.
- 15 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1203
Open AccessInvestigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach
Background: Bladder cancer (BC) is a common malignancy in the urinary system, with an increasing incidence rate. Immune cell infiltration within the tumor microenvironment (TME) plays a crucial role in BC progression and treatment response. However, the immune cell composition of the TME presents a significant challenge to the effectiveness of current therapeutic strategies. Methods: We performed bidirectional Mendelian randomization (MR) analysis to investigate the impact of immune cells on BC risk. Single nucleotide polymorphisms (SNPs) related to immune cells were annotated, and candidate genes associated with BC risk were identified. Differential expression analysis identified immune-related differentially expressed genes (iDEGs), and a protein–protein interaction (PPI) network along with functional enrichment analysis were conducted to explore their roles in tumor development. Machine learning-based feature selection was applied to identify potential biomarkers and therapeutic targets. Results: MR analysis revealed eight immune cell subtypes significantly associated with BC. Using SNPs linked to these immune cells, 129 candidate genes were identified through the SNPense tool and cross-referenced with differentially expressed genes in BC, resulting in identification of 28 iDEGs. Machine learning identified five potential diagnostic biomarkers (COLEC12, TMCC1, CEP55, KLK3, COL4A1) with an AUC of 0.903, which are implicated in immune modulation and cancer progression. Conclusions: This study provides new insights into immune mechanisms in BC and identifies promising biomarkers for early diagnosis and therapeutic intervention.
- Open Access
- 7 February 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (7) , 2143-2152
Impact of flow rate and ratio of endoscope-sheath diameter on stone removal in flexible ureteroscopic lithotripsy: in vitro and CFD analyses insights
Purpose To develop a theoretical framework for stone removal in flexible ureteroscopic lithotripsy (FURL) using a soft-tip negative pressure ureteral access sheath (SNP-UAS), we examined how flow rate (FR) and ratio of endoscope-sheath diameter (RESD) affect maximum pull-back speed (max-PBS) through in vitro experiments and computational fluid dynamics (CFD) analyses. Furthermore, we sought to initially clarify the principles behind stone movement in FURL. Methods Two sub-studies examined the effects of FR and RESD on PBS during SNP-UAS-assisted FURL while focusing on the principles of stone movement. The first sub-study involved in vitro experiments that referenced the male urinary tract, using an appropriately curved SNP-UAS with a 0.30 cm ball as a stone model. Initially, the minimum FR required for effective max-PBS in in vitro experiments was observed under a commonly used RESD (0.73) and FR between 20.00 and 50.00 ml/min. Subsequently, variations in max-PBS were analyzed across three RESD values (0.73, 0.79, and 0.87) and available FR levels (50.00, 70.00, and 90.00 ml/min). The second sub-study involved CFD analyses utilizing a simplified model, with an SNP-UAS oriented vertically and a circle of 0.30 cm diameter as stone model. Initially, circle’s movement was examined at a PBS of 0.00 cm/s, RESD of 0.73, and FR from 20.00 to 100.00 ml/min, with preliminary movement principles explained. Next, circle’s movement was assessed at a PBS of 5.00 cm/s, FR of 50.00 ml/min, and RESD values of 0.73, 0.79, and 0.87. Results In the first sub-study, only the 50.00 ml/min FR group achieved the max-PBS, and max-PBS increased with higher FR and larger RESD. In the second sub-study, at FR of 50.00 ml/min and above, the circle ascended faster towards the water inlet as FR increased. During the circle’s accelerated and uniform movement phase, the pressure surrounding it balanced, but vortices persisted and changed. At FR 50.00 ml/min and 5.00 cm/s PBS, higher RESD led to quicker and further circle ascent. Conclusion In vitro experiments and CFD analyses reveal that higher RESD and FR enhance PBS during FURL using SNP-UAS, aiding individual stone removal. The stone movement is directly driven by surrounding vortices, not pressure differences.
- 7 February 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (7) , 2143-2152
Open AccessImpact of flow rate and ratio of endoscope-sheath diameter on stone removal in flexible ureteroscopic lithotripsy: in vitro and CFD analyses insights
Purpose To develop a theoretical framework for stone removal in flexible ureteroscopic lithotripsy (FURL) using a soft-tip negative pressure ureteral access sheath (SNP-UAS), we examined how flow rate (FR) and ratio of endoscope-sheath diameter (RESD) affect maximum pull-back speed (max-PBS) through in vitro experiments and computational fluid dynamics (CFD) analyses. Furthermore, we sought to initially clarify the principles behind stone movement in FURL. Methods Two sub-studies examined the effects of FR and RESD on PBS during SNP-UAS-assisted FURL while focusing on the principles of stone movement. The first sub-study involved in vitro experiments that referenced the male urinary tract, using an appropriately curved SNP-UAS with a 0.30 cm ball as a stone model. Initially, the minimum FR required for effective max-PBS in in vitro experiments was observed under a commonly used RESD (0.73) and FR between 20.00 and 50.00 ml/min. Subsequently, variations in max-PBS were analyzed across three RESD values (0.73, 0.79, and 0.87) and available FR levels (50.00, 70.00, and 90.00 ml/min). The second sub-study involved CFD analyses utilizing a simplified model, with an SNP-UAS oriented vertically and a circle of 0.30 cm diameter as stone model. Initially, circle’s movement was examined at a PBS of 0.00 cm/s, RESD of 0.73, and FR from 20.00 to 100.00 ml/min, with preliminary movement principles explained. Next, circle’s movement was assessed at a PBS of 5.00 cm/s, FR of 50.00 ml/min, and RESD values of 0.73, 0.79, and 0.87. Results In the first sub-study, only the 50.00 ml/min FR group achieved the max-PBS, and max-PBS increased with higher FR and larger RESD. In the second sub-study, at FR of 50.00 ml/min and above, the circle ascended faster towards the water inlet as FR increased. During the circle’s accelerated and uniform movement phase, the pressure surrounding it balanced, but vortices persisted and changed. At FR 50.00 ml/min and 5.00 cm/s PBS, higher RESD led to quicker and further circle ascent. Conclusion In vitro experiments and CFD analyses reveal that higher RESD and FR enhance PBS during FURL using SNP-UAS, aiding individual stone removal. The stone movement is directly driven by surrounding vortices, not pressure differences.